€6.6M 2-year extension for Ablynx from BI
This article was originally published in Scrip
Executive Summary
Ablynx announced a two-year extension of its five-year research agreement established in September 2007 with Boehringer Ingelheim to discover, develop and commercialise up to ten different Nanobody therapeutics. Ablynx will receive a total of €6.6 million in additional research funding from Boehringer Ingelheim, some of which will be in advance.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.